Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07185997 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
A Phase 3 study of Non-Small Cell Lung Cancer and Metastatic Non Small Cell Lung Cancer, sponsored by ArriVent BioPharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
- 20
- Study locations
NCT07185997 is a Phase 3 study of Non-Small Cell Lung Cancer and Metastatic Non Small Cell Lung Cancer that is actively recruiting participants, run by ArriVent BioPharma. The registered enrollment target is 480 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT07185997, a Phase 3 study of Non-Small Cell Lung Cancer and Metastatic Non Small Cell Lung Cancer, is actively recruiting participants, sponsored by ArriVent BioPharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC mutations, and who have not received any prior therapy for advanced disease. Participants will be randomized in a 1:1 ratio to treatment with firmonertinib or osimertinib or afatinib and will take the assigned dose daily.
Conditions Studied
Interventions
- DRUG Firmonertinib
- DRUG EGFR-TKI inhibitor based on investigator's choice
Study Locations (20)
Other
- Humanity and Health Clinical Trial Centre - Central
- National Cancer Centre Singapore - Singapore
- Curie Oncology (Farrer) - Singapore
- Gachon University Gil Medical Center - Incheon
Virginia
- University of Virginia - Charlottesville
- Virginia Cancer Specialists - Fairfax
- Shenandoah Oncology, P.C. - Winchester
California
- University of California Davis Comprehensive Cancer Center - Sacramento
- UCSF Medical Center-Mission Bay - San Francisco
Texas
- Texas Oncology - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
Aichi-ken
- Aichi Cancer Center - Nagoya
Fukuoka
- Kurume University Hospital - Kurume-Shi
Hokkaido
- National Hospital Organization Hokkaido Cancer Center - Sapporo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2030-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07185997
The ClinicalTrials.gov registry entry for NCT07185997 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (27% lower). The listed sponsor is ArriVent BioPharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Firmonertinib is the first listed.
NCT07185997 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Virginia, California.
Frequently Asked Questions
What is clinical trial NCT07185997 about?
NCT07185997 is a clinical study titled "Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations". Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC ...
What is the current status of trial NCT07185997?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2025-12-17. Estimated completion is 2030-12.
What conditions does trial NCT07185997 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, Egfr Pacc.
What interventions are being tested in trial NCT07185997?
The interventions under investigation include: Firmonertinib (DRUG), EGFR-TKI inhibitor based on investigator's choice (DRUG).
Who is sponsoring clinical trial NCT07185997?
This trial is sponsored by ArriVent BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07185997 being conducted?
This trial has 20 study locations across California, New York, Texas, Virginia, Aichi-ken. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Explore more on PlainTrial
Non-Small Cell Lung Cancer
All registered trials for this condition
Metastatic Non Small Cell Lung Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.